Application of molecular modeling to urokinase inhibitors development

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Sulimov, V B ^a,b   Katkova, E V ^a,b   Oferkin, I V ^a,b   Sulimov, A V ^a,b   Romanov, A N ^a   Roschin, A I ^a   Beloglazova, I B ^c   Plekhanova, O S ^c   Tkachuk, V A ^a,c   Sadovnichiy, V A ^a  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b Dimonta Ltd   (Russian Federation)

^c INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BENZISOTHIAZOL 3 YL GUANIDINE; 5 BROMO 1,2 BENZISOTHIAZOL 3 YL; ANTINEOPLASTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR; UNCLASSIFIED DRUG; UROKINASE; PLASMA PROTEIN;

AB INITIO CALCULATION; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHEMICAL STRUCTURE; CONTROLLED STUDY; DISCORE PROGRAM; DRUG BINDING SITE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLM PROGRAM; IC 50; IN VITRO STUDY; LIGAND BINDING; METASTASIS; MOLECULAR DOCKING; MOLECULAR MODEL; PROTEIN DATA BANK; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTUM CHEMISTRY; SOL PROGRAM; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPUTER PROGRAM; HUMAN;

BLOOD PROTEINS; DRUG DESIGN; HUMANS; MOLECULAR DOCKING SIMULATION; SOFTWARE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84902156497     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/625176     Document Type: Article

References (71)

1. Sadovnichy V. A., Sulimov V. B., Supercomputer technology in science, education and industry. Supercomputer Technologies in Medicine 16 23. 2009 (Russian)
2. Duffy M. J., The urokinase plasminogen activator system: role in malignancy. Current Pharmaceutical Design 2004 10 1 39 49 2-s2.0-0347917028 10.2174/1381612043453559 (Pubitemid 38072742)
3. Choong P. F. M., Nadesapillai A. P. W., Urokinase plasminogen activator system: a multifunction role in tumor progression and metastasis. Clinical Orthopaedics and Related Research 2003 415 S46 S58 2-s2.0-0142188116 (Pubitemid 37323319)
4. Blasi F., Carmeliet P., uPAR: a versatile signalling orchestrator. Nature Reviews Molecular Cell Biology 2002 3 12 932 943 2-s2.0-0036906177 10.1038/nrm977 (Pubitemid 35477371)
5. Plekhanova O. S., Parfyonova Y. V., Bibilashvily R. S., Stepanova V. V., Erne P., Bobik A., Tkachuk V. A., Urokinase plasminogen activator enhances neointima growth and reduces lumen size in injured carotid arteries. Journal of Hypertension 2000 18 8 1065 1069 2-s2.0-0033851467
6. Ulisse S., Baldini E., Sorrenti S., D'Armiento M., The urokinase plasminogen activator system: a target for anti-cancer therapy. Current Cancer Drug Targets 2009 9 1 32 71 2-s2.0-62549113036 10.2174/156800909787314002
7. Gondi C. S., Lakka S. S., Dinh D. H., Olivero W. C., Gujrati M., Rao J. S., Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type Plasminogen Activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clinical Cancer Research 2007 13 14 4051 4060 2-s2.0-34547134691 10.1158/1078-0432.CCR-06-3032 (Pubitemid 47105965)
8. Hofmeister V., Schrama D., Becker J. C., Anti-cancer therapies targeting the tumor stroma. Cancer Immunology, Immunotherapy 2008 57 1 1 17 2-s2.0-35748943826 10.1007/s00262-007-0365-5 (Pubitemid 350043655)
9. Li Y., Cozzi P. J., Targeting uPA/uPAR in prostate cancer. Cancer Treatment Reviews 2007 33 6 521 527 2-s2.0-34548414532 10.1016/j.ctrv.2007.06. 003 (Pubitemid 47355340)
10. Spraggon G., Phillips C., Nowak U. K., Ponting C. P., Saunders D., Dobson C. M., Stuart D. I., Jones E. Y., The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 1995 3 7 681 691 2-s2.0-0029645121
11. Béné M. C., Castoldi G., Knapp W., Rigolin G. M., Escribano L., Lemez P., Ludwig W.-D., Matutes E., Orfao A., Lanza F., van't Veer M., CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia 2004 18 3 394 400 2-s2.0-1542503922 10.1038/sj.leu.2403250 (Pubitemid 38425850)
12. Irigoyen J. P., Muñoz-Cánoves P., Montero L., Koziczak M., Nagamine Y., The plasminogen activator system: biology and regulation. Cellular and Molecular Life Sciences 1999 56 1-2 104 132 2-s2.0-0033213996 (Pubitemid 29471930)
13. Pepper M. S., Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 7 1104 1117 2-s2.0-0035721955 (Pubitemid 34215137)
14. Kirchheimer J. C., Wojta J., Christ G., Binder B. R., Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proceedings of the National Academy of Sciences of the United States of America 1989 86 14 5424 5428 2-s2.0-2042503759 (Pubitemid 19185561)
15. Ossowski L., Reich E., Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983 35 3 611 619 2-s2.0-0021045628 (Pubitemid 14168365)
16. Graf L., Craik C. S., Patthy A., Roczniak S., Fletterick R. J., Rutter W. J., Selective alteration of substrate specificity by replacement of aspartic acid-189 with lysine in the binding pocket of trypsin. Biochemistry 1987 26 9 2616 2623 2-s2.0-0023176519 (Pubitemid 17081493)
17. Stürzebecher J., Markwardt F., Synthetic inhibitors of serine proteinases. 17. The effect of benzamidine derivatives on the activity of urokinase and the reduction of fibrinolysis. Pharmazie 1978 33 9 599 602 2-s2.0-0018012761
18. Vassalli J.-D., Belin D., Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Letters 1987 214 1 187 191 2-s2.0-0023646314
19. Yang H., Henkin J., Kim K. H., Greer J., Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. Journal of Medicinal Chemistry 1990 33 11 2956 2961 2-s2.0-0025155112 (Pubitemid 20349520)
20. Towle M. J., Lee A., Maduakor E. C., Schwartz C. E., Bridges A. J., Littlefield B. A., Inhibition of urokinase by 4-substituted benzo[b]thiophene-2- carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Research 1993 53 11 2553 2559 2-s2.0-0027314501 (Pubitemid 23168022)
21. Bruncko M., McClellan W. J., Wendt M. D., Sauer D. R., Geyer A., Dalton C. R., Kaminski M. A., Weitzberg M., Gong J., Dellaria J. F., Mantei R., Zhao X., Nienaber V. L., Stewart K., Klinghofer V., Bouska J., Rockway T. W., Giranda V. L., Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. Bioorganic and Medicinal Chemistry Letters 2005 15 1 93 98 2-s2.0-9644303125 10.1016/j.bmcl.2004.10.026 (Pubitemid 39575790)
22. Spencer J. R., McGee D., Allen D., Katz B. A., Luong C., Sendzik M., Squires N., Mackman R. L., 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Bioorganic and Medicinal Chemistry Letters 2002 12 15 2023 2026 2-s2.0-0037025461 10.1016/S0960-894X(02)00312-8 (Pubitemid 34756473)
23. Barber C. G., Dickinson R. P., Horne V. A., Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-pyridinylguanidines. Bioorganic and Medicinal Chemistry Letters 2002 12 2 181 184 2-s2.0-0037147798 10.1016/S0960-894X(01)00701-6 (Pubitemid 34037962)
24. Barber C. G., Dickinson R. P., Fish P. V., Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-Isoquinolinylguanidines. Bioorganic and Medicinal Chemistry Letters 2004 14 12 3227 3230 2-s2.0-2442618968 10.1016/j.bmcl.2004.03.094 (Pubitemid 38624597)
25. Fish P. V., Barber C. G., Brown D. G., Butt R., Collis M. G., Dickinson R. P., Henry B. T., Horne V. A., Huggins J. P., King E., O'Gara M., McCleverty D., McIntosh F., Phillips C., Webster R., Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines. Journal of Medicinal Chemistry 2007 50 10 2341 2351 2-s2.0-34248992886 10.1021/jm061066t (Pubitemid 46799246)
26. Frederickson M., Callaghan O., Chessari G., Congreve M., Cowan S. R., Matthews J. E., McMenamin R., Smith D.-M., Vinković M., Wallis N. G., Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. Journal of Medicinal Chemistry 2008 51 2 183 186 2-s2.0-38349184176 10.1021/jm701359z
27. Heynekamp J. J., Hunsaker L. A., Vander Jagt T. A., Deck L. M., Vander Jagt D. L., Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator. BMC Chemical Biology 2006 6, article no. 1 2-s2.0-33745115242 10.1186/1472-6769-6-1 (Pubitemid 43895908)
28. Zhu M., Gokhale V. M., Szabo L., Munoz R. M., Baek H., Bashyam S., Hurley L. H., Von Hoff D. D., Han H., Identification of a novel inhibitor of urokinase-type plasminogen activator. Molecular Cancer Therapeutics 2007 6 4 1348 1356 2-s2.0-34248189716 10.1158/1535-7163.MCT-06-0520 (Pubitemid 46711998)
29. Subasinghe N. L., Illig C., Hoffman J., Rudolph M. J., Wilson K. J., Soll R., Randle T., Green D., Lewandowski F., Zhang M., Bone R., Spurlino J., DesJarlais R., Deckman I., Molloy C. J., Manthey C., Zhou Z., Sharp C., Maguire D., Crysler C., Grasberger B., Structure-Based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors. Bioorganic and Medicinal Chemistry Letters 2001 11 11 1379 1382 2-s2.0-0035806134 10.1016/S0960-894X(01)00247-5 (Pubitemid 32510825)
30. Sperl S., Jacob U., Arroyo de Prada N., Stürzebecher J., Wilhelm O. G., Bode W., Magdolen V., Huber R., Moroder L., (4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. Proceedings of the National Academy of Sciences of the United States of America 2000 97 10 5113 5118 2-s2.0-0034624980 10.1073/pnas.97.10.5113 (Pubitemid 30313680)
31. Ertongur S., Lang S., Mack B., Wosikowski K., Muehlenweg B., Gires O., Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. International Journal of Cancer 2004 110 6 815 824 2-s2.0-2942591963 10.1002/ijc.20192 (Pubitemid 38758506)
32. The Protein Data Bank. http://www.rcsb.org
33. Sadovnichy V. A., Sulimov V. B., Katkova E. V., Romanov A. N., Sulimov A. V., Oferkin I. V., Stambolsky D. V., Beloglazova I. B., Tkachuk V. A., Application of molecular modeling to urokinase inhibitors design. Post-Genomic Research and Technologies Moscow, Russia MSU 103 140. 2011 (Russian)
34. Sulimov A. V., Kutov D. C., Oferkin I. V., Katkova E. V., Sulimov V. B., Application of the docking program SOL for CSAR Benchmark. Journal of Chemical Information and Modeling 2013 53 8 1946 1956 10.1021/ci400094h
35. Halgren T. A., Merck molecular force field. I. Basis, form, scope, parametrization and performance of MMFF94. Journal of Computational Chemistry 1996 17 5-6 490 519 (Pubitemid 126567067)
36. Halgren T. A., Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. Journal of Computational Chemistry 1996 17 5-6 520 552 (Pubitemid 126567068)
37. Halgren T. A., Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94. Journal of Computational Chemistry 1996 5-6 553 586 (Pubitemid 126567069)
38. Halgren T. A., Nachbar R. B., Merck molecular force field. IV. Conformational energies and geometries for MMFF94. Journal of Computational Chemistry 1996 17 5-6 587 615 (Pubitemid 126567070)
39. Halgren T. A., Merck molecular force field. V. Extension of MMFF94 using experimenatal data, additional computational data and empirical rules. Journal of Computational Chemistry 1996 17 5-6 616 641 (Pubitemid 126567071)
40. Romanov A. N., Kondakova O. A., Grigoriev F. V., Sulimov A. V., Luschekina S. V., The SOL docking package for computer-aided drug design. Numerical Methods and Programing 9 2 213 233. 2008 (Russian)
41. Oferkin I. V., Sulimov A. V., Kondakova O. A., Sulimov V. B., Implementation of parallel computing for docking programs SOLGRID and SOL. Numerical Methods and Programing 12 1 205 219. 2011 (Russian)
42. Romanov A. N., Jabin S. N., Martynov Y. B., Sulimov A. V., Grigoriev F. V., Sulimov V. B., Surface generalized born method: a simple, fast, and precise implicit solvent model beyond the coulomb approximation. Journal of Physical Chemistry A 2004 108 43 9323 9327 2-s2.0-8344229165 10.1021/jp046721s
43. Validation of SOL program. http://www.keenbase.ru
44. Nocedal J., Wright S. J., Numerical Optimization 2006 New York, NY, USA Springer Science+Business Media
45. Kupervasser O. Y., Zhabin S. N., Martynov Y. B., Fedulov K. M., Oferkin I. V., Sulimov A. V., Sulimov V. B., Continual model of solvent: the DISOLV software-algorithms, implementation, and validation. Numerical Methods and Programing 12 246 261. 2011 (Russian)
46. Sulimov V. B., Katkova E. V., Oferkin I. V., Kochugaeva M. P., PCM, COSMO, and Surface GB implementation in program DISOLV: development and validation. Proceedings of the 244th ACS National Meeting 2012 Philadelphia, Pa, USA. oral presentation COMP 441
47. Schwarzl S. M., Tschopp T. B., Smith J. C., Fischer S., Can the calculation of ligand binding free energies be improved with continuum solvent electrostatics and an ideal-gas entropy correction? Journal of Computational Chemistry 2002 23 12 1143 1149 2-s2.0-0036722785 10.1002/jcc.10112 (Pubitemid 34854445)
48. Stewart J. J. P., MOPAC. 2012, http://openmopac.net
49. MOZYME. http://www.openmopac.net/MOZYME
50. Stewart J. J. P., Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters. Journal of Molecular Modeling 2013 19 1 32
51. Řezáč J., Fanfrlík J., Salahub D., Hobza P., Semiempirical quantum chemical PM6 method augmented by dispersion and H-bonding correction terms reliably describes various types of noncovalent complexes. Journal of Chemical Theory and Computation 2009 5 7 1749 1760 2-s2.0-67849101722 10.1021/ct9000922
52. Korth M., Pitoňák M., Řezáč J., Hobza P., A transferable H-bonding correction for semiempirical quantum-chemical methods. Journal of Chemical Theory and Computation 2010 6 344 352 10.1021/ct900541n
53. Korth M., Third-generation hydrogen-bonding corrections for semiempirical QM methods and force fields. Journal of Chemical Theory and Computation 2010 6 12 3808 3816 2-s2.0-78651286289 10.1021/ct100408b
54. Řezáč J., Hobza P., A halogen-bonding correction to the semiempirical PM6 method. Chemical Physics Letters 2011 506 266 289
55. Berger C., Weber-Bornhauser S., Eggenberger J., Hanes J., Plückthun A., Bosshard H. R., Antigen recognition by conformational selection. FEBS Letters 1999 450 1-2 149 153 2-s2.0-0032966864 10.1016/S0014-5793(99)00458-5 (Pubitemid 29206729)
56. Foote J., Milstein C., Conformational isomerism and the diversity of antibodies. Proceedings of the National Academy of Sciences of the United States of America 1994 91 22 10370 10374 2-s2.0-0027943261 10.1073/pnas.91.22.10370 (Pubitemid 24328998)
57. Kumar S., Ma B., Tsai C.-J., Sinha N., Nussinov R., Folding and binding cascades: dynamic landscapes and population shifts. Protein Science 2000 9 1 10 19 2-s2.0-0033970020 (Pubitemid 30070934)
58. Tsai C.-J., Ma B., Nussinov R., Folding and binding cascades: shifts in energy landscapes. Proceedings of the National Academy of Sciences of the United States of America 1999 96 18 9970 9972 2-s2.0-0033621104 10.1073/pnas.96.18. 9970 (Pubitemid 29422488)
59. Landau L. D., Lifshitz E. M., Statistical Physics, Part 1 1980 5 3rd Butterworth-Heinemann
60. Landau L. D., Lifshitz E. M., Mechanics 1976 1 3rd Butterworth-Heinemann
61. Claeson G., Friberger P., Knos M., Eriksson E., Methods for determination of prekallikrein in plasma, glandular kallikrein and urokinase. Haemostasis 1978 7 2-3 76 78 2-s2.0-0018190512 (Pubitemid 8360719)
62. Zolton R. P., Synthetic peptide substrate assays for hemostasis testing. Advances in Clinical Chemistry 1986 25 117 168 2-s2.0-0022485827 10.1016/S0065-2423(08)60125-0
63. Klon A. E., Glick M., Thoma M., Acklin P., Davies J. W., Finding more needles in the haystack: a simple and efficient method for improving high-throughput docking results. Journal of Medicinal Chemistry 2004 47 11 2743 2749 2-s2.0-2442716437 10.1021/jm030363k (Pubitemid 38656727)
64. Hajduk P. J., Boyd S., Nettesheim D., Nienaber V., Severin J., Smith R., Davidson D., Rockway T., Fesik S. W., Identification of novel inhibitors of urokinase via NMR-based screening. Journal of Medicinal Chemistry 2000 43 21 3862 3866 2-s2.0-0034687240 10.1021/jm0002228
65. Developmental Therapeutics Program NCI/NIH. http://dtp.nci.nih.gov
66. Katz B. A., Sprengeler P. A., Luong C., Verner E., Elrod K., Kirtley M., Janc J., Spencer J. R., Breitenbucher J. G., Hui H., McGee D., Allen D., Martelli A., Mackman R. L., Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. Chemistry and Biology 2001 8 11 1107 1121 2-s2.0-0035194282 10.1016/S1074-5521(01)00084-9 (Pubitemid 33119187)
67. ZINC Database. http://zinc.docking.org
68. ACBBlocks Database. http://www.acbblocks.com
69. Vitas-M Database. http://www.vitasmlab.com
70. Sinauridze E. I., Romanov A. N., Gribkova I. V., Kondakova O. A., Surov S. S., Gorbatenko A. S., Butylin A. A., Monakov M. Y., Bogolyubov A. A., Kuznetsov Y. V., Sulimov V. B., Ataullakhanov F. I., New synthetic thrombin inhibitors: molecular design and experimental verification. PLoS ONE 2011 6 5 2-s2.0-79956150472 10.1371/journal.pone.0019969 e19969
71. Nienaber V. L., Richardson P. L., Klighofer V., Bouska J. J., Giranda V. L., Greer J., Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nature Biotechnology 2000 18 10 1105 1108 2-s2.0-0033773899